Kornimate/medical-research-clean huggingface dataset:
pilot for a community pharmacy service model: impact of a pharmacist monitored patient blood pressure readings

Conditions: Hypertension

Summary: this study is designed to explore whether routine measurement of blood pressure by community pharmacists can improve patient adherence to blood pressure medications. the study will utilize an incentivized care approach, in which patients receive a $10 gift card for every time they come to the pharmacy for blood pressure management (up to 2 times/month). the investigators hypothesize that the simple process of coming in for a blood pressure measurement (without any other scripted interventions, counseling, or consultation) will be feasible and sufficient to improve adherence to medications. the investigators will also collect preliminary data to help estimate how these hypothetical improvements in adherence might result in improved blood pressure control, fewer office visits, and (ultimately) fewer adverse cardiovascular outcomes (i.e. heart attacks, strokes, etc).


Eligibility criteria:
inclusion criteria: * age ≥18 years * diagnosis of hypertension * current prescription for ≥2 antihypertensive medications for primary diagnosis of hypertension * prior use of ≥1 antihypertensive medication for ≥6 months at the same kroger's pharmacy (#523) * willing and able to provide written informed consent exclusion criteria: * age \<18 years * new diagnosis of hypertension within the prior 6 months * current pregnancy or lactation * limited english proficiency * use of antihypertensive medications for secondary prevention of cardiovascular events. patients with history of acute myocardial infarction, stroke, heart failure will be excluded, however, patients with diabetes will be eligible for participation.
or v iv antibiotics for infection

Conditions: Joint Infection

Summary: management of periprosthetic joint infection (pji) commonly includes 6 weeks of intravenous (iv) antibiotics after surgical treatment. however, there is little evidence to suggest that oral (po) therapy results in worse outcomes. this study aims to determine whether or not po antibiotics are non-inferior to iv antibiotics in treating pji. the study is a multicenter, parallel-group, randomized (1 : 1), open-label, non-inferiority trial. the non-inferiority margin will be set at 10%. adults with a clinical diagnosis of pji according to the international consensus meeting (icm) criteria who would ordinarily receive at least 6 weeks of antibiotics and have received ≤ 7 days of iv therapy from surgery will be included. a total of 308 participants will be centrally computer-randomized to po or iv antibiotics to complete the first 6 weeks of therapy. follow-on po therapy will be permitted in either arm. the primary outcome is the proportion of participants experiencing treatment failure within 1 year. an associated cost-effectiveness evaluation including complications, resource utilization and quality-of-life data will be performed.


Eligibility criteria:
inclusion criteria: * aged ≥ 18 years * willing and able to give informed consent * primary tha or tka diagnosed with pji based on international consensus meeting criteria 1. a sinus communicating with the prosthesis or 2. two positive cultures obtained from the prosthesis or 3. 3 of 5 criteria: * elevated esr (\>30mm/hr) and crp (\>10mg/l) * elevated synovial leukocyte count (\>3000 cells/µl) or change of ++ on leukocyte esterase strip * elevated synovial neutrophil percentage (\>80%) * one positive culture * positive histological analysis of periprosthetic tissue (\>5 neutrophils per high power field in 5 high power fields x400) * pji treated by debridement and implant retention, or excision of the prosthetic joint (with or without planned reimplantation) * received ≤ 7 days of iv therapy after an appropriate surgical intervention exclusion criteria: * previously treated for native septic arthritis or pji in the same joint * s. aureus bacteremia on presentation or within the previous month * clinical, histological or microbiological evidence of mycobacterial, fungal or parasitic etiology of the infection * any other concomitant infection that, in the opinion of the clinician responsible for the patient, requires a prolonged course of iv antibiotic therapy (e.g. bacterial endocarditis, mediastinal infection, central nervous system infection) * septic shock or systemic features that, in the opinion of the clinician responsible for the patient, requires a course of iv antibiotic therapy (the patient could be re-evaluated if these features resolved) * an infection for which there are no suitable antibiotic choices to permit randomization between the two arms of the trial (e.g. when organisms are only sensitive to iv antibiotics or po antibiotics) * unlikely to comply with trial requirements following randomization in the opinion of the investigator
a caspase inhibitor in chronic hepatitis c (hcv) patients

Conditions: Hepatitis C, Chronic

Summary: the purpose of this study is to determine if idn-6556, when given orally, is safe and effective in patients with chronic hepatitis c virus infection.


Eligibility criteria:
inclusion criteria: * chronic hepatitis c infection * unsuccessful prior hcv treatment * liver impairment (either ast or alt 1.5-10.0 x uln) * alpha-fetoprotein \<= 50 ng/ml * adequate hematologic parameters exclusion criteria: * decompensated or severe liver disease * hepatocellular carcinoma * hiv infection * co-infection with hepatitis b virus (hbv) * renal impairment * pancreatitis * use of illicit or drugs of abuse * history of alcohol abuse * presence of clinically significant cardiac arrhythmias * if female, pregnant or lactating
effect of facilitated tucking and gentle human touch on procedural pain among neonates

Conditions: Non Pharmacological Pain Management

Summary: this is a randomized control trial intended to investigate the effect of two non-pharmacological interventions on procedural pain among neonates.

the study design is a randomized control trial, intended to investigate the effect of facilitated tucking and gentle human touch on procedural pain among neonates (age 28 days). neonatal infant pain scale will be used for pain scoring, data will be collected by recording demographic variables for all neonates and then capturing a video recording for pain scoring by an independent research assistant.

Eligibility criteria:
inclusion criteria: 1. both term and preterm neonates. 2. apgar scores of a minimum of 6 at one minute and 8 at 5 minutes 3. admitted to the neonatal intensive care unit 4. undergoing arterial prick for the first time. exclusion criteria: 1. documented birth asphyxia 2. congenital anomalies 3. neurological diagnosis, 4. ventilated with paralysis 5. extremely premature newborns (gestational age \< 28 weeks)

Keywords: non pharmacological pain management neonates procedural pain
acupoint thermal radiation characteristics in adolescents with mdd

Conditions: Major Depression

Summary: modern studies have confirmed that skin temperature changes at acupoints when the body is under pathological conditions. this suggests that changes in the thermal radiation characteristics of acupoints can objectively respond to the symptoms of a disease. in this study, the investigators first evaluated reproducibility of acupoint temperature measurement by irt. secondly, the investigators explored the thermal radiation characteristics of mdd-related acupoints, built the diagnostic model for adolescent depression severity and the diagnostic model for mdd in adolescents based on acupoint temperature. our research findings will provide new ideas, methods and visualisations for early screening, auxiliary diagnosis and condition assessment of mdd in adolescents.

a total of 100 subjects were included, 60 adolescent with mdd (mdd group) and 40 healthy controls (hc group). all subjects accepted irt detection.the random selection of 30 adolescent with mdd allowed the collection of the bilateral same name acupoint temperatures. intra- and inter-observer reproducibility for the patients were examined in some randomly selected patients by 2 investigators and 2 investigators both made 2 independent measurements in a week. 30 mdd subjects were detected the bilateral same name acupoint temperatures.

Eligibility criteria:
inclusion criteria: inclusion criteria for the healthy control participants: * 12years≤ age\<18 years; * sds score \<53; * adolescents with normal cognitive function can cooperate with the study; * adolescents and guardians agree to the study plan and sign the informed consent form. inclusion criteria for the major depression disorder participants: * 12years≤ age\<18 years; * self-rating depression scale (sds) score ≥ 53; * language, cognition and communication ability are normal; * patients and guardians agree to the study plan and sign the informed consent form. exclusion criteria: exclusion criteria both for the healthy control participants and major depression disorder participants: * severe anxiety, schizophrenia, or other serious mental illnesses; * there are pigmentation, redness, infection or scarring on the skin at the site of detection; * patients with severe systemic diseases and their complications, serious infections, and major diseases of viscera, tissues, and systems; * female patients who were pregnant or lactating; * female patients who were during, or in proximity (±2 days) to their menstruation or ovulation; * patients with a body temperature ≥37.3°c; * inability to cooperate during the examination; * participating in any other clinical trials.

Keywords: major depression disorder acupoint temperature adolescent
treatment of group a beta hemolytic streptococcal pharyngitis in children in low resource settings

Conditions: Streptococcal Infections; Pharyngitis

Summary: the purpose of this study was to compare the microbiological effects of two different treatments: a single dose of intramuscular benzathine penicillin g (im bpg) vs. a 10-day daily dose of amoxicillin for the treatment of gabhs pharyngitis in children in low resource settings. this study was a prospective multi-center randomized active control treatment trial. the trial is a non-inferiority equivalence trial, to determine if amoxicillin treatment is at least as effective as the currently given im bpg treatment.


Eligibility criteria:
inclusion criteria: * age: 2-12 years old, * presenting with complaint of sore throat * parental consent given and child assent if 5 years or older exclusion criteria: * the parent/guardian reported oral antibiotic use in the past 3 days or injectable penicillin in past 28 days prior to screening * had a history of rheumatic fever or rheumatic heart disease * required hospitalization for any reason at the time of enrollment * had previously been enrolled in the study

Keywords: streptococcal pharyngitis randomized clinical trial amoxicillin intramuscular benzathine penicillin g.
new biomarkers of bone mineral metabolism as cardiovascular risk factors in chronic kidney disease patients

Conditions: Chronic Kidney Disease

Summary: to evaluate the relationships between bone mineral metabolism markers (osteoprotegerin, fibroblast growth factor 23) at inclusion and the occurence of cardiovascular events during a 7 year follow-up.


Eligibility criteria:
inclusion criteria: * patient who has signed the written consent form * patient with chronic renal failure defined by glomerular filtration rate (gfr) but without dialysis therapy exclusion criteria: * pregnancy * patient with chronic renal failure requiring dialysis therapy

Keywords: chronic kidney disease vascular calcifications cardiovascular risk
treatment of alopecic scars by follicular unit extraction hair transplantation

Conditions: Alopecia Scar

Summary: this study aim: is to completely hide the alopecic scars in a way that it will not be visible.

practicing scar revision, there is an increasing demand for almost complete reconstruction and camouflaging scars in hairy areas rather than scars in non-hairy skin. scar revision rendered insufficient reconstructive tool in such cases. whatever a plastic surgeon pay efforts in alopecic scars rejuvenation and reconstruction, it is still apparent and noticeable. one of the best surgical techniques to camouflage an alopecic scar is hair transplantation. fue is the state-of-the-art technique for hair transplantation. in the field of hair restoration, there has been a significant increase in demand with patients for facial hair transplantation procedures. modern techniques in hair transplantation is based on follicular unit extraction and implantation, in which follicular units are the exclusive structures used as hair grafts allow for facial hair transplantation and for the attainment of natural-appearing results. facial hair transplantation is a subspecialty within hair restoration with many gratifying benefits for the patients as well as for the hair restoration surgeon. adapting these advanced techniques into a hair restoration practice allows a surgeon to offer their patients these procedures and provides an expanded artistic element to a hair restoration surgeon's practice. the art and science of hair transplantation have come a long way since its introduction in 1959. both the technique and instruments have been greatly improved, thus offering the patient an excellent cosmetic result that will last a lifetime.

Eligibility criteria:
inclusion criteria: * small scalp alopecic scars. * post traumatic alopecic beard scars * post traumatic alopecic moustache scars. * post traumatic alopecic scalp scars. * post traumatic alopecic eyebrow scars. * post burn small alopecic scars. * mature scars. * controlled infective scars. exclusion criteria: * large alopecic scars * post burn alaopecic scar * uncontrolled active scar * male pattern baldness * female pattern baldness
a pragmatic trial comparing empagliflozin and dapagliflozin through cluster randomization embedded in the electronic health record

Conditions: Diabetes Mellitus, Type 2; Heart Failure; Chronic Kidney Diseases

Summary: the aim of this clinical trial is investigate the comparative effectiveness of empagliflozin and dapagliflozin for the treatment of diabetes, chronic kidney disease, and heart failure. patients who are prescribed either empagliflozin or dapagliflozin, as part of daily clinical practice at the participating sites, will be included in the study. treatment will be randomized automatically through the electronic health record software in clusters defined by time of day. https://www.appletreestudy.com


Eligibility criteria:
inclusion criteria: * adults aged 18 years or more exclusion criteria: * incapabability of giving informed consent * withdrawal of informed consent
optimalisation of the treatment of acute neonatal hyperammonaemia

Conditions: Hyperammonemic Encephalopathy

Summary: acute neonatal hyperammonemia is associated with poor neurological outcomes and high mortality. a user-friendly and widely applicable algorithm - based on kinetics - to tailor the treatment of acute neonatal hyperammonemia. a single compartmental model was calibrated assuming a distribution volume equal to the patient's total body water (v), as calculated using wells' formula, and dialyzer clearance as derived from the measured ammonia time-concentration curves during 11 dialysis sessions in four patients (3.2 +/- 0.4 kg). based on these kinetic simulations, dialysis protocols could be derived for clinical use with different body weights, start concentrations, dialysis machines/dialyzers and dialysis settings (e.g., blood flow qb). by a single measurement of ammonia concentration at the dialyzer inlet and outlet, dialyzer clearance (k) can be calculated as k = qb\[(cinlet - coutlet)/cinlet\]. the time (t) needed to decrease the ammonia concentration from a predialysis start concentration cstart to a desired target concentration ctarget is then equal to t = (-v/k)ln(ctarget/cstart). by implementing these formulae in a simple spreadsheet, medical staff can draw an institution-specific flowchart for patient-tailored treatment of hyperammonemia. the aim of this study is to validate these formula with a prospective study.


Eligibility criteria:
inclusion criteria: * severe acute neonatal hyperammonaemia for which acute hemodialysis is indicated * inborn error of metabolism * below 1 year of age exclusion criteria: * older than 1 year

Keywords: hemodialysis neonate hyperammonemic encephalopathy inborn error of metbolism
phase ii trial of doxil, carboplatin, bevacizumab in triple negative untreated metastatic breast cancer

Conditions: Metastatic Breast Cancer

Summary: the purpose of this research study is to look at the effectiveness of a combination of doxil, carboplatin and bevacizumab on metastatic breast cancer. the type of breast cancer being studied is negative for a protein called her2/neu and for estrogen receptors (er) and progesterone receptors (pr). her2/neu, er and pr are part of a family of receptors found on both cancer and normal cells. this family of receptors is important for cell growth and is found in many tumor types.this study is being conducted for the following research purposes:· to find out what effects, if any, the study drug has on metastatic breast cancer. for instance, will the study drug cause the tumor(s) to shrink or stop growing?· to test the safety of the study drugs and to see what affects it has. for instance, are there any side effects? if so, what kind of side effects does the study drug cause? how severe are the side effects, and how often do they occur?· to see if the study drugs have any effect on keeping the disease from getting worse.


Eligibility criteria:
inclusion criteria: 1. women with previously untreated metastatic breast cancer, er/pr/her2/neu negative. 2. age \>= 18 3. ecog performance status \<= 2 4. normal organ and marrow function 5. normal cardiac function as evidenced by lvef within institutional normal limits exclusion criteria: 1. history of hypersensitivity reactions to doxil or bevacizumab 2. myocardial infarct or unstable angina within 6 months before enrollment 3. prior anthracycline dose exceeding 360 mg/m2 for doxorubicin (including doxil) or 720 mg/m2 for epirubicin. 4. proteinuria

Keywords: negative for a protein called her2/neu negative for estrogen receptors (er) and progesterone receptors (pr). breast cancer
eliciting perceived norms about substance use

Conditions: Tobacco Use; Alcohol Drinking

Summary: survey experiment to elicit perceived norms about substance use

health behaviors and health risk behaviors are known to be associated with the extent to which one perceives these behaviors as normative. the canonical example of this phenomenon is taken from the u.s. literature, which has robustly shown that undergraduate students on college campuses tend to drink more heavily and frequently if they believe their classmates drink heavily and frequently, irrespective of their classmates' actual levels and frequency of use. however, there remains little systematic understanding about the best ways to elicit these perceived norms through survey-based research studies. this randomized survey experiment compares different ways of eliciting perceived norms.

Eligibility criteria:
inclusion criteria: * all adults who consider nyakabare their primary place of residence and who are capable of providing consent exclusion criteria: * minors younger than 18 years of age, with the exception of emancipated minors * persons who do not consider nyakabare parish their primary place of residence, e.g., persons who happen to be visiting nyakabare at the time of the survey or who own a home in nyakabare but spend most of their time outside the parish * persons with psychosis, neurological damage, acute intoxication, or other cognitive impairment (all of which are determined informally in the field by non-clinical research staff in consultation with a supervisor)
phase ii study of cisplatin plus epirubicin salvage chemo in refractory germ cell tumors

Conditions: Germ Cell Tumor

Summary: this study proposes to evaluate the combination of cisplatin plus epirubicin in patients with refractory germ cell tumor not amendable to cure with surgery or standard platinum salvage chemotherapy. this regimen will be used in eligible patients after progression on ecog study e39897.

to determine the feasibility and toxicity of combining epirubicin to fixed does cisplatin; to determine the partial and complete response rate and duration of remission; to determine the toxicity; to ascertain the potential for greater than 12 month continuous disease-free survival and, therefore, potential curability.

Eligibility criteria:
inclusion criteria: * histologic or serologic proof of metastatic germ cell neoplasm(gonadal or extragonadal primary) w/ disease not amenable to cure with either surgery or chemotherapy. pts w/ seminoma \& non-seminoma are eligible, as are women w/ ovarian germ cell tumors. * must have failed initial cisplatin combination therapy administered w/ curative intent. in addition, pts should have failed and demonstrated progressive disease following the administration of at least one "salvage" regimen for advanced germ cell neoplasms unless they have primary mediastinal nonseminomatous germ cell tumor, or are considered to be a late relapse (\>2 yrs since becoming a complete response). * pts must have adequate system function (wbc\>/= 4,000 \& plts \>/=100,000; sgot \</=4x normal; bilirubin \</=2.0; serum crt \</=2.5) obtained \</= 4 wks prior to entry. * ecog performance status of 0,1, or 2. * pts must be at least 3 weeks post major surgery, radiotherapy, or chemotherapy, and have recovered from all toxicity. * exclusion criteria: * active, unresolved infection and/or are receiving concurrent treatment w/ parenteral antibiotics. \*eligible after antibiotics have been discontinued for at least 7 days. * pregnant or lactating * progression w/in 4 wks of lst course of cisplatin combination chemotherapy.

Keywords: germ cell tumor refractory germ cell tumors cisplatin plus epirubicin salvage chemotherapy
retention rate of acalabrutinib in a non-interventional setting

Conditions: Chronic Lymphocytic Leukaemia (CLL)

Summary: retention rate of acalabrutinib in a non-interventional setting. this is a prospective, multicentre, non-interventional study to collect real-world data on retention rates of cll patients prescribed with acalabrutinib in germany.

this observational study will prospectively assess acalabrutinib therapy retention of cll patients one year and 2 years after treatment initiation with acalabrutinib in routine clinical practice. furthermore, therapy adherence, treatment efficacy, overall survival, and qol to analyse the possible influence of psychological aspects of the patient-based disease perception, a four-group-segmentation for acceptance and perceived control of the health state will be conducted. finally, disease-, treatment-, and patient-specific factors possibly affecting therapy retention will be analysed: sociodemographic factors, disease and treatment characteristics, comorbidities, therapy adherence, treatment effectiveness, safety, qol, and psychological segmentation.

Eligibility criteria:
inclusion criteria: * age ≥ 18 years * diagnosis of cll * ability to understand the study concept and to regularly complete patient questionnaires from physical, mental, and linguistic perspectives * decision to start therapy with acalabrutinib according to the current smpc. for previously untreated patients as continuous therapy with or without obinutuzumab. or for patients with at least one prior cll therapy as continuous monotherapy. * provision of signed informed consent form exclusion criteria: * current or planned participation in an interventional clinical trial * contraindications to treatment with acalabrutinib according to the current smpc * pregnancy or breast feeding * disease progression on prior btki therapy * start of acalabrutinib therapy more than 28 days prior to enrolment

Keywords: acalabrutinib